Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA OKs new pancreatic cancer drug trialed at Dana-Farber

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at wcvb.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

The FDA has expedited approval for daraxonrasib, a novel pancreatic cancer drug developed partly at Dana-Farber that targets a mutated protein in over 90% of cases, significantly extending patient survival compared to standard chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

You can pivot quickly to include daraxonrasib in your pancreatic cancer pipeline development or clinical offering, as the FDA has cleared a clear path for patient access and potential insurance coverage.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-cancerdaraxonrasibclinical-trialsbiotech